Prioritisation is crucial for the success of PrEP, model confirms
Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis
Inter-connecting health problems increase HIV risk for MSM
Civacir immune globulin may help prevent HCV reinfection after liver transplant
Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients
Truvada PrEP causes only mild loss of bone mineral density
People with hepatitis C have higher cancer rates, even when excluding liver cancer
Modern NNRTI regimens can be effective with 85% adherence
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis
